Text Size:AAA

GM-CSF / CSF2 抗體, 兔多抗, 抗原親和純化

產品資料評論實驗方法
描述: Active  
表達宿主: Human Cells  
  • Slide 1
10015-H07H-500
10015-H07H-5
10015-H07H-20
10015-H07H-100
10015-H07H-1
500 µg 
5 µg 
20 µg 
100 µg 
1 mg 
Add to Cart
描述: Active  
表達宿主: Human Cells  
  • Slide 1
10015-H01H-5
10015-H01H-20
10015-H01H-100
5 µg 
20 µg 
100 µg 
Add to Cart
表達宿主: Yeast  
  • Slide 1
10015-HNAY-500
10015-HNAY-5
10015-HNAY-20
10015-HNAY-100
10015-HNAY-1
500 µg 
5 µg 
20 µg 
100 µg 
1 mg 
Add to Cart
表達宿主: Human Cells  
  • Slide 1
10015-HNAH-5
10015-HNAH-20
10015-HNAH-100
5 µg 
20 µg 
100 µg 
Add to Cart
表達宿主: Human Cells  
  • Slide 1
51048-MNAH-50
51048-MNAH-20
50 µg 
20 µg 
Add to Cart
表達宿主: Human Cells  
  • Slide 1
51048-M07H-50
51048-M07H-20
50 µg 
20 µg 
Add to Cart
表達宿主: Human Cells  
  • Slide 1
51048-M01H-50
51048-M01H-20
50 µg 
20 µg 
Add to Cart
表達宿主: Human Cells  
  • Slide 1
80020-R07H-50
80020-R07H-20
50 µg 
20 µg 
Add to Cart
表達宿主: Human Cells  
  • Slide 1
80020-R01H-50
80020-R01H-20
50 µg 
20 µg 
Add to Cart

GM-CSF/CSF2 ELISA配對抗體

檢測限: 9.4 pg/ml
SEK10015-5
SEK10015-15
5 Plates 
15 Plates 
Add to Cart

GM-CSF/CSF2 AntibodyRelated Products

Related Products

Featured Reagent Products

GM-CSF/CSF2 antibody 研究背景

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 (cellular) immune responses in cognate T cells. The active form of the protein is found extracellularly as a homodimer, and the encoding gene is localized to a related gene cluster at chromosome region 5q31 which is known to be associated with 5q-syndrome and acute myelogenous leukemia. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients. GM-CSF deficiency in pregnancy adversely impacts fetal and placental development, as well as progeny viability and growth after birth, highlighting this cytokine as a central maternal determinant of pregnancy outcome with clinical relevance in human fertility.

Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

大鼠 GM-CSF/CSF2 antibody 參考資料
  • Robertson SA. (2007) GM-CSF regulation of embryo development and pregnancy. Cytokine Growth Factor Rev. 18(3-4): 287-98.
  • Waller EK. (2007) The role of sargramostim (rhGM-CSF) as immunotherapy. Oncologist. 12 Suppl 2: 22-6.
  • Clive KS, et al. (2010) Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Expert Rev Vaccines. 9(5): 519-25.
  • 請注意:所有產品都是“僅用於科研,而不能用於診斷或治療用途”